BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Salomon JJ, Ehrhardt C. Organic cation transporters in the blood-air barrier: expression and implications for pulmonary drug delivery. Ther Deliv 2012;3:735-47. [PMID: 22838069 DOI: 10.4155/tde.12.51] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.9] [Reference Citation Analysis]
Number Citing Articles
1 Jain KK. Current status and future prospects of drug delivery systems. Methods Mol Biol 2014;1141:1-56. [PMID: 24567129 DOI: 10.1007/978-1-4939-0363-4_1] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.9] [Reference Citation Analysis]
2 Salomon JJ, Galeron P, Schulte N, Morow PR, Severynse-Stevens D, Huwer H, Daum N, Lehr CM, Hickey AJ, Ehrhardt C. Biopharmaceutical in vitro characterization of CPZEN-45, a drug candidate for inhalation therapy of tuberculosis. Ther Deliv 2013;4:915-23. [PMID: 23919471 DOI: 10.4155/tde.13.62] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
3 Otter M, Oswald S, Siegmund W, Keiser M. Effects of frequently used pharmaceutical excipients on the organic cation transporters 1–3 and peptide transporters 1/2 stably expressed in MDCKII cells. European Journal of Pharmaceutics and Biopharmaceutics 2017;112:187-95. [DOI: 10.1016/j.ejpb.2016.11.028] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
4 Tan JM, Karthivashan G, Arulselvan P, Fakurazi S, Hussein MZ. Sustained Release and Cytotoxicity Evaluation of Carbon Nanotube-Mediated Drug Delivery System for Betulinic Acid. Journal of Nanomaterials 2014;2014:1-11. [DOI: 10.1155/2014/862148] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
5 Ugwu MC, Oli A, Esimone CO, Agu RU. Organic cation rhodamines for screening organic cation transporters in early stages of drug development. J Pharmacol Toxicol Methods 2016;82:9-19. [PMID: 27235784 DOI: 10.1016/j.vascn.2016.05.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
6 Salomon JJ, Muchitsch VE, Gausterer JC, Schwagerus E, Huwer H, Daum N, Lehr C, Ehrhardt C. The Cell Line NCl-H441 Is a Useful in Vitro Model for Transport Studies of Human Distal Lung Epithelial Barrier. Mol Pharmaceutics 2014;11:995-1006. [DOI: 10.1021/mp4006535] [Cited by in Crossref: 72] [Cited by in F6Publishing: 68] [Article Influence: 9.0] [Reference Citation Analysis]
7 Sakamoto A, Matsumaru T, Yamamura N, Suzuki S, Uchida Y, Tachikawa M, Terasaki T. Drug Transporter Protein Quantification of Immortalized Human Lung Cell Lines Derived from Tracheobronchial Epithelial Cells (Calu-3 and BEAS2-B), Bronchiolar–Alveolar Cells (NCI-H292 and NCI-H441), and Alveolar Type II-like Cells (A549) by Liquid Chromatography–Tandem Mass Spectrometry. Journal of Pharmaceutical Sciences 2015;104:3029-38. [DOI: 10.1002/jps.24381] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 4.3] [Reference Citation Analysis]
8 Al-Jayyoussi G, Price DF, Francombe D, Taylor G, Smith MW, Morris C, Edwards CD, Eddershaw P, Gumbleton M. Selectivity in the impact of P-glycoprotein upon pulmonary absorption of airway-dosed substrates: a study in ex vivo lung models using chemical inhibition and genetic knockout. J Pharm Sci. 2013;102:3382-3394. [PMID: 23670704 DOI: 10.1002/jps.23587] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
9 Ali-Seyed M, Jantan I, Vijayaraghavan K, Bukhari SN. Betulinic Acid: Recent Advances in Chemical Modifications, Effective Delivery, and Molecular Mechanisms of a Promising Anticancer Therapy. Chem Biol Drug Des 2016;87:517-36. [PMID: 26535952 DOI: 10.1111/cbdd.12682] [Cited by in Crossref: 80] [Cited by in F6Publishing: 68] [Article Influence: 11.4] [Reference Citation Analysis]
10 Verma RK, Ibrahim M, Garcia-contreras L. Lung Anatomy and Physiology and Their Implications for Pulmonary Drug Delivery. In: Nokhodchi A, Martin GP, editors. Pulmonary Drug Delivery. Chichester: John Wiley & Sons, Ltd; 2015. pp. 1-18. [DOI: 10.1002/9781118799536.ch1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
11 Kell DB, Dobson PD, Bilsland E, Oliver SG. The promiscuous binding of pharmaceutical drugs and their transporter-mediated uptake into cells: what we (need to) know and how we can do so. Drug Discov Today 2013;18:218-39. [PMID: 23207804 DOI: 10.1016/j.drudis.2012.11.008] [Cited by in Crossref: 109] [Cited by in F6Publishing: 95] [Article Influence: 10.9] [Reference Citation Analysis]
12 Salomon JJ, Hagos Y, Petzke S, Kühne A, Gausterer JC, Hosoya K, Ehrhardt C. Beta-2 Adrenergic Agonists Are Substrates and Inhibitors of Human Organic Cation Transporter 1. Mol Pharm 2015;12:2633-41. [PMID: 25751092 DOI: 10.1021/mp500854e] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
13 Selo MA, Sake JA, Ehrhardt C, Salomon JJ. Organic Cation Transporters in the Lung-Current and Emerging (Patho)Physiological and Pharmacological Concepts. Int J Mol Sci 2020;21:E9168. [PMID: 33271927 DOI: 10.3390/ijms21239168] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
14 Ingoglia F, Visigalli R, Rotoli BM, Barilli A, Riccardi B, Puccini P, Dall'Asta V. Functional characterization of the organic cation transporters (OCTs) in human airway pulmonary epithelial cells. Biochim Biophys Acta 2015;1848:1563-72. [PMID: 25883089 DOI: 10.1016/j.bbamem.2015.04.001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
15 Salomon JJ, Gausterer JC, Yahara T, Hosoya K, Huwer H, Hittinger M, Schneider-Daum N, Lehr CM, Ehrhardt C. Organic cation transporter function in different in vitro models of human lung epithelium. Eur J Pharm Sci 2015;80:82-8. [PMID: 26296865 DOI: 10.1016/j.ejps.2015.08.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
16 Macdonald C, Shao D, Oli A, Agu RU. Characterization of Calu-3 cell monolayers as a model of bronchial epithelial transport: organic cation interaction studies. J Drug Target 2013;21:97-106. [PMID: 23050869 DOI: 10.3109/1061186X.2012.731068] [Cited by in Crossref: 22] [Cited by in F6Publishing: 4] [Article Influence: 2.2] [Reference Citation Analysis]
17 Shao D, Massoud E, Anand U, Parikh A, Cowley E, Clarke D, Agu RU. Organic cation transporters in human nasal primary culture: expression and functional activity. Ther Deliv 2013;4:439-51. [PMID: 23557285 DOI: 10.4155/tde.13.10] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
18 Mukherjee M, Cingolani E, Pritchard DI, Bosquillon C. Enhanced expression of Organic Cation Transporters in bronchial epithelial cell layers following insults associated with asthma - Impact on salbutamol transport. Eur J Pharm Sci 2017;106:62-70. [PMID: 28549677 DOI: 10.1016/j.ejps.2017.05.052] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
19 Kell DB. Finding novel pharmaceuticals in the systems biology era using multiple effective drug targets, phenotypic screening and knowledge of transporters: where drug discovery went wrong and how to fix it. FEBS J. 2013;280:5957-5980. [PMID: 23552054 DOI: 10.1111/febs.12268] [Cited by in Crossref: 81] [Cited by in F6Publishing: 67] [Article Influence: 9.0] [Reference Citation Analysis]
20 Berg T, Hegelund-Myrbäck T, Öckinger J, Zhou XH, Brännström M, Hagemann-Jensen M, Werkström V, Seidegård J, Grunewald J, Nord M, Gustavsson L. Expression of MATE1, P-gp, OCTN1 and OCTN2, in epithelial and immune cells in the lung of COPD and healthy individuals. Respir Res 2018;19:68. [PMID: 29678179 DOI: 10.1186/s12931-018-0760-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
21 Pasqua E, Hamblin N, Edwards C, Baker-Glenn C, Hurley C. Developing inhaled drugs for respiratory diseases: A medicinal chemistry perspective. Drug Discov Today 2021:S1359-6446(21)00394-9. [PMID: 34547449 DOI: 10.1016/j.drudis.2021.09.005] [Reference Citation Analysis]
22 Ibrahim M, Garcia-Contreras L. Mechanisms of absorption and elimination of drugs administered by inhalation. Ther Deliv. 2013;4:1027-1045. [PMID: 23919477 DOI: 10.4155/tde.13.67] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
23 Al-jayyoussi G, Price DF, Kreitmeyr K, Keogh JP, Smith MW, Gumbleton M, Morris CJ. Absorption of ipratropium and l -carnitine into the pulmonary circulation of the ex-vivo rat lung is driven by passive processes rather than active uptake by OCT/OCTN transporters. International Journal of Pharmaceutics 2015;496:834-41. [DOI: 10.1016/j.ijpharm.2015.10.036] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
24 Salomon JJ, Gausterer JC, Selo MA, Hosoya KI, Huwer H, Schneider-Daum N, Lehr CM, Ehrhardt C. OCTN2-Mediated Acetyl-l-Carnitine Transport in Human Pulmonary Epithelial Cells In Vitro. Pharmaceutics 2019;11:E396. [PMID: 31394757 DOI: 10.3390/pharmaceutics11080396] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
25 Li D, Qi C, Zhou J, Wen Z, Zhu X, Xia H, Song J. LPS-induced inflammation delays the transportation of ASP+ due to down-regulation of OCTN1/2 in alveolar epithelial cells. J Drug Target 2020;28:437-47. [PMID: 31591905 DOI: 10.1080/1061186X.2019.1678169] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.7] [Reference Citation Analysis]
26 Ehrhardt C, Bäckman P, Couet W, Edwards C, Forbes B, Fridén M, Gumbleton M, Hosoya K, Kato Y, Nakanishi T, Takano M, Terasaki T, Yumoto R. Current Progress Toward a Better Understanding of Drug Disposition Within the Lungs: Summary Proceedings of the First Workshop on Drug Transporters in the Lungs. Journal of Pharmaceutical Sciences 2017;106:2234-44. [DOI: 10.1016/j.xphs.2017.04.011] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
27 Nickel S, Clerkin CG, Selo MA, Ehrhardt C. Transport mechanisms at the pulmonary mucosa: implications for drug delivery. Expert Opinion on Drug Delivery 2016;13:667-90. [DOI: 10.1517/17425247.2016.1140144] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 5.5] [Reference Citation Analysis]
28 Han S, Chandel NS. Lessons from Cancer Metabolism for Pulmonary Arterial Hypertension and Fibrosis. Am J Respir Cell Mol Biol 2021;65:134-45. [PMID: 33844936 DOI: 10.1165/rcmb.2020-0550TR] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]